Contributions
Abstract: PB1733
Type: Publication Only
Background
Core-binding factor-positive acute myeloid leukemia (CBF-AML) (t(8;21)
or inv(16)/t(16;16)) is associated with favorable prognosis. However, first relapse of AML-CBF occurs in 30% to 40% patients and can still be cured in half of patients. A number of studies identify predictive factors of outcome in relapsed CBF-AML which may help to improve post-relapse therapy strategies.
Aims
to determine risk factors for relapse in CBF-AML and to report clinical outcome of relapsed CBF-AML.
Methods
his single-center study involved 74 patients with de novo AML with rearrangement of CBF genes during the period between January 2006 and December 2017. We assessed clinical, biological, histological and cytogenetic characteristics for relapse and outcome of relapsed CBF-AML. Risk factors were identified using univariate and multivariate analysis. Kaplan-Meier method is used to estimate overall survival (OS).
Results
Among the 74 CBF-AML patients, 21 (28.4 %) patients relapsed. Median age at relapse was 52 years (range, 28-64 years); inv(16) had 5/21 (23.8%) and t(8;21) 16/21 (76.2%) of patients) The median duration for CR1 was 20 months (range, 1-132 months) for inv(16) and 12 months (range, 1-120 months) for t(8;21) (p=0.051). Univariate analysis detected the following significant risk factors for relapse in CBF-AML: age ≥50 years (p = 0.039), CD56+ (p < 0.001). Multivariate analysis identified CD56+ as the most important risk factor for relapse in CBF-AML (p = 0.001; relative risk (RR) = 0.59; 95% confidental interval (CI) = 0.011-0.308). The median OS for all the patients after relapse was 24 months (2-132 months); 25 months (range 2-132 months) for those with inv(16) and 18 months (range, 3 - 132 months) for those with t(8;21) (p=0.551). The CR2 rate for the inv(16) and the t(8;21) was 80% and 53.3%, respectively (p=0.630). Univariate analysis detected the following significant risk factors for poor OS in relapsed CBF-AML patients: elevated LDH (p=0.05), CD56+ (p=0.05) and t(8;21) (p= 0.045). Multivariate analysis identified t(8;21) as the most important risk factor for poor OS in relapsed CBF-AML (p = 0.045; relative risk (RR) = 3.171; 95% confidental interval (CI) = 0.891-11.283).
Conclusion
According to the results obtained from the analysis, CBF-AML with CD56+ have a higher risk of relapse. Among patients with relapsed CBF-AML, the outcome was worse in patients with t(8;21).
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, Core binding factor leukemia, Relapse
Abstract: PB1733
Type: Publication Only
Background
Core-binding factor-positive acute myeloid leukemia (CBF-AML) (t(8;21)
or inv(16)/t(16;16)) is associated with favorable prognosis. However, first relapse of AML-CBF occurs in 30% to 40% patients and can still be cured in half of patients. A number of studies identify predictive factors of outcome in relapsed CBF-AML which may help to improve post-relapse therapy strategies.
Aims
to determine risk factors for relapse in CBF-AML and to report clinical outcome of relapsed CBF-AML.
Methods
his single-center study involved 74 patients with de novo AML with rearrangement of CBF genes during the period between January 2006 and December 2017. We assessed clinical, biological, histological and cytogenetic characteristics for relapse and outcome of relapsed CBF-AML. Risk factors were identified using univariate and multivariate analysis. Kaplan-Meier method is used to estimate overall survival (OS).
Results
Among the 74 CBF-AML patients, 21 (28.4 %) patients relapsed. Median age at relapse was 52 years (range, 28-64 years); inv(16) had 5/21 (23.8%) and t(8;21) 16/21 (76.2%) of patients) The median duration for CR1 was 20 months (range, 1-132 months) for inv(16) and 12 months (range, 1-120 months) for t(8;21) (p=0.051). Univariate analysis detected the following significant risk factors for relapse in CBF-AML: age ≥50 years (p = 0.039), CD56+ (p < 0.001). Multivariate analysis identified CD56+ as the most important risk factor for relapse in CBF-AML (p = 0.001; relative risk (RR) = 0.59; 95% confidental interval (CI) = 0.011-0.308). The median OS for all the patients after relapse was 24 months (2-132 months); 25 months (range 2-132 months) for those with inv(16) and 18 months (range, 3 - 132 months) for those with t(8;21) (p=0.551). The CR2 rate for the inv(16) and the t(8;21) was 80% and 53.3%, respectively (p=0.630). Univariate analysis detected the following significant risk factors for poor OS in relapsed CBF-AML patients: elevated LDH (p=0.05), CD56+ (p=0.05) and t(8;21) (p= 0.045). Multivariate analysis identified t(8;21) as the most important risk factor for poor OS in relapsed CBF-AML (p = 0.045; relative risk (RR) = 3.171; 95% confidental interval (CI) = 0.891-11.283).
Conclusion
According to the results obtained from the analysis, CBF-AML with CD56+ have a higher risk of relapse. Among patients with relapsed CBF-AML, the outcome was worse in patients with t(8;21).
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, Core binding factor leukemia, Relapse